Genetic testing helps identify cause of neonatal cholestasis
Genetic testing can help doctors find the cause of neonatal cholestasis more quickly, so children can receive more targeted treatment sooner, according to a…
News
Hoth, VA partner on head-to-head study in fatty liver disease mice
Hoth Therapeutics will support a U.S. Department of Veterans Affairs (VA) study testing treatment with glial cell-derived neurotrophic factor (GDNF) against semaglutide in a…
Study reveals disease mechanisms that may drive biliary atresia
A new preclinical study has found that a combination of viral and bacterial insults may be a key disease mechanism underlying biliary atresia. Specifically,…
World Hepatitis Day is aiming for a world without viral hepatitis
World Hepatitis Day arrives Monday and advocates are gearing up to break down barriers that stand in the way of a world free from…
PPAR agonists effective in UDCA-resistant primary biliary cholangitis
A class of medicines called PPAR agonists that modulate genes involved in inflammation and scarring improve biochemical markers of liver function and ease itching in…
Bylvay eases itching in episodic PFIC1, boosting daily life: Study
Bylvay (odevixibat) eased pruritus — itching — during episodes of progressive familial intrahepatic cholestasis (PFIC) type 1 caused by mutations in both copies of…
Madrigal wins US patent for Rezdiffra dosing regimen in MASH
The U.S. Patent and Trademark Office (USPTO) is granting a patent for Rezdiffra (resmetirom) — Madrigal Pharmaceuticals’ approved therapy for metabolic dysfunction-associated steatohepatitis (MASH),…
Scientists ID ways to aid Alagille syndrome diagnosis in infants
In infants younger than 3 months, identifying heart problems and distinctive facial features, as well as blood markers and certain liver tissue abnormalities, may aid…
Hepatitis C treatment rates low among some at-risk US populations
Access to hepatitis C treatment and care remains low among children and recently pregnant women in the U.S., according to data from two recently…
Umecrine raises $2.5M to advance trial testing golexanolone for PBC
Umecrine Cognition has raised around $2.5 million to support an ongoing Phase 1b/2a clinical trial testing its investigational therapy golexanolone for cognitive problems and…
Recent Posts
- How I find healthy foods on a budget while living with MASH
- AI tool uses liver tests to ID genetic forms of cholestasis in infants
- Preparing my son with Alagille syndrome, and myself, for surgery
- Fatty liver disease linked to projected rise in liver cancer
- Study finds a new player behind liver scarring in biliary atresia